SG11201808992UA - Compositions and methods for the detection of host cell proteins - Google Patents

Compositions and methods for the detection of host cell proteins

Info

Publication number
SG11201808992UA
SG11201808992UA SG11201808992UA SG11201808992UA SG11201808992UA SG 11201808992U A SG11201808992U A SG 11201808992UA SG 11201808992U A SG11201808992U A SG 11201808992UA SG 11201808992U A SG11201808992U A SG 11201808992UA SG 11201808992U A SG11201808992U A SG 11201808992UA
Authority
SG
Singapore
Prior art keywords
international
compositions
pct
methods
april
Prior art date
Application number
SG11201808992UA
Inventor
Guojie Mao
Original Assignee
Lonza Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Ag filed Critical Lonza Ag
Publication of SG11201808992UA publication Critical patent/SG11201808992UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER (19) World Intellectual Property -, Organization International Bureau ... ...j (43) International Publication Date ......„.... 19 October 2017(19.10.2017) WIPO I PCT THE PATENT COOPERATION TREATY (PCT) 1111111101111011101010111110101111101110101111111111110101111101111101111011111 (10) International Publication Number WO 2017/178526 Al (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (71) (72) International Patent Classification: (81) G01N 33/543 (2006.01) C07K 16/00 (2006.01) International Application Number: PCT/EP2017/058775 International Filing Date: 12 April 2017 (12.04.2017) English English Priority Data: 62/322,621 14 April 2016 (14.04.2016) US (84) Applicant: LONZA LTD [CH/CH]; Lonzastrasse, 3930 Visp (CH). Inventor: MAO, Guojie; Lonza Biologics Pls, 228 Bath Road, Slough Berkshire SL1 (GB). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, [Continued on next page] Title: COMPOSITIONS AND METHODS FOR THE DETECTION OF HOST CELL PROTEINS tall \".,..g.rk 1.•*; , r ., cell abSe lect Sure Chrornatoeraohl , ' ' titration /Concentratil c :'::,'-, Chromatogra Fig. 1 (57) compositions combinant protein, e.g., an antibody. : Disclosed herein are, inter alia, methods and useful for detecting and/or quantifying host proteins during the production of a product, e.g., a re- (54) 1-1 ei kin cc IN ,—, IN ,—, ,..= ei O WO 2017/178526 Al MIDEDIMOMONIIMOMOMOINIERIONIIMOVOIS LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, before the expiration of the time limit for amending the SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, claims and to be republished in the event of receipt of GW, KM, ML, MR, NE, SN, TD, TG). amendments (Rule 48.2(h)) Published: — with international search report (Art. 21(3))
SG11201808992UA 2016-04-14 2017-04-12 Compositions and methods for the detection of host cell proteins SG11201808992UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322621P 2016-04-14 2016-04-14
PCT/EP2017/058775 WO2017178526A1 (en) 2016-04-14 2017-04-12 Compositions and methods for the detection of host cell proteins

Publications (1)

Publication Number Publication Date
SG11201808992UA true SG11201808992UA (en) 2018-11-29

Family

ID=58645011

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808992UA SG11201808992UA (en) 2016-04-14 2017-04-12 Compositions and methods for the detection of host cell proteins

Country Status (13)

Country Link
US (3) US11353468B2 (en)
EP (2) EP3443348A1 (en)
JP (1) JP2019516964A (en)
KR (1) KR102408260B1 (en)
CN (2) CN115109148A (en)
AU (1) AU2017251360A1 (en)
BR (1) BR112018071107A2 (en)
CA (1) CA3020808A1 (en)
EA (1) EA201892325A1 (en)
IL (2) IL290358B2 (en)
MX (1) MX2018012550A (en)
SG (1) SG11201808992UA (en)
WO (1) WO2017178526A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808992UA (en) 2016-04-14 2018-11-29 Lonza Ag Compositions and methods for the detection of host cell proteins
US11268951B2 (en) * 2017-09-20 2022-03-08 Charles River Laboratories International, Inc. CHO host cell protein assay
CN109078628B (en) * 2018-08-27 2021-06-11 西北大学 High-efficiency hydrophobic interaction chromatographic medium with benzylamine as ligand, preparation method and application of medium in protein renaturation and purification
CN111665364A (en) * 2019-03-08 2020-09-15 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 Method for evaluating coverage rate of polyclonal antibody for HCP detection
KR20220107586A (en) 2021-01-25 2022-08-02 금오공과대학교 산학협력단 Detection Device for Cell Population using Electric Signal and Detection Method using the same
WO2024084264A1 (en) * 2022-10-17 2024-04-25 HAJIAN TEHRANI, Behrooz Immunoassay for detecting host cell proteins of high five cells
CN115894677A (en) * 2022-12-01 2023-04-04 湖州申科生物技术股份有限公司 Antibody combination for improving HCP detection antibody coverage rate and application thereof
CN117192107A (en) * 2023-09-11 2023-12-08 福建基诺厚普生物科技有限公司 Detection method and kit for process-specific host cell protein residues

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (en) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Day and date setting device for clocks with calendar
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US6797522B1 (en) * 1994-01-13 2004-09-28 The Trustees Of Columbia University In The City Of New York Synthetic receptors
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU2199099A (en) * 1997-12-31 1999-07-19 Genentech Inc. Real-time monitoring of an analyte by chromatography using an on-line assay
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US20030091976A1 (en) * 2001-11-14 2003-05-15 Ciphergen Biosystems, Inc. Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry
WO2004094989A2 (en) * 2003-04-22 2004-11-04 Ciphergen Biosystems, Inc. Methods of host cell protein analysis
US20080261249A1 (en) * 2004-01-13 2008-10-23 Genentech, Inc Detecting and Quantifying Host Cell Proteins in Recombinant Protein Products
US8728828B2 (en) * 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
CN101571549B (en) * 2008-04-30 2013-08-14 上海泽润生物科技有限公司 Vero cell HCP test kit and application thereof
WO2010141039A1 (en) * 2008-10-20 2010-12-09 Abbott Laboratories Isolation and purification of antibodies using protein a affinity chromatography
ES2706190T3 (en) * 2012-10-30 2019-03-27 Hoffmann La Roche Purification of polypeptides using two-phase tangential flow ultrafiltration
CN103439512B (en) * 2013-07-30 2014-05-07 通化东宝药业股份有限公司 Method for detecting specific recombinant human insulin escherichia coli residual host protein
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
CN103792366B (en) * 2014-01-21 2015-09-23 内蒙古必威安泰生物科技有限公司 Aftosa vaccine host cell proteins Double-antibody sandwich enzymelinked immunosorbent detection kit and using method
CN105021824A (en) * 2015-07-06 2015-11-04 上海优者生物科技有限公司 ELISA kit for quantitative determination of residual CHO host cell protein in biomedical products and usage method thereof
SG11201808992UA (en) * 2016-04-14 2018-11-29 Lonza Ag Compositions and methods for the detection of host cell proteins

Also Published As

Publication number Publication date
US20220268792A1 (en) 2022-08-25
JP2019516964A (en) 2019-06-20
US20190128903A1 (en) 2019-05-02
WO2017178526A1 (en) 2017-10-19
AU2017251360A1 (en) 2018-11-01
EA201892325A1 (en) 2019-04-30
US11353468B2 (en) 2022-06-07
CN109564217A (en) 2019-04-02
BR112018071107A2 (en) 2019-04-16
EP3683579A1 (en) 2020-07-22
KR20180129927A (en) 2018-12-05
MX2018012550A (en) 2019-07-08
KR102408260B1 (en) 2022-06-10
CN115109148A (en) 2022-09-27
EP3443348A1 (en) 2019-02-20
IL290358A (en) 2022-04-01
CA3020808A1 (en) 2017-10-19
IL290358B2 (en) 2024-03-01
US20220268791A1 (en) 2022-08-25
IL290358B1 (en) 2023-11-01
IL262297A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
SG11201808992UA (en) Compositions and methods for the detection of host cell proteins
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201909777YA (en) Modulatory polynucleotides
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201909011PA (en) Niraparib compositions
SG11201809331RA (en) Antibodies recognizing tau
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201811015RA (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201901140QA (en) Compounds and methods for reducing tau expression
SG11201901172QA (en) A method for manufacturing a fuel component
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201804704PA (en) Compositions and methods for decreasing tau expression